Running marathons or endurance races is often seen as a hallmark of peak fitness. However, a groundbreaking new study led by Inova oncologist Tim Cannon, MD, Sheridan Director, Molecular Tumor Board and Co-Director of the Gastrointestinal Cancer Program at Inova Schar Cancer, reveals a surprising prevalence of precancerous colon growths among extreme runners. Recently featured in The New York Times, the study opens new discussions about screening opportunities.
Article links:
With new research published every week and the endless stream of nutrition information and opinions…
A major new study led by Wayne Batchelor, MD, an interventional cardiologist and President of…
Spring 2026 Safety Grade is a national recognition for commitment to patient safety Fairfax, VA…
When you walk into Letta’s treatment room on infusion day, a small disco ball throws…
Fairfax, VA – Inova Schar Cancer has been approved for a funding award from the…
Not all mental health struggles look the same. Inova offers a full range of behavioral…